Literature DB >> 19793821

Acute infection with venezuelan equine encephalitis virus replicon particles catalyzes a systemic antiviral state and protects from lethal virus challenge.

Jennifer L Konopka1, Joseph M Thompson, Alan C Whitmore, Drue L Webb, Robert E Johnston.   

Abstract

The host innate immune response provides a critical first line of defense against invading pathogens, inducing an antiviral state to impede the spread of infection. While numerous studies have documented antiviral responses within actively infected tissues, few have described the earliest innate response induced systemically by infection. Here, utilizing Venezuelan equine encephalitis virus (VEE) replicon particles (VRP) to limit infection to the initially infected cells in vivo, a rapid activation of the antiviral response was demonstrated not only within the murine draining lymph node, where replication was confined, but also within distal tissues. In the liver and brain, expression of interferon-stimulated genes was detected by 1 to 3 h following VRP footpad inoculation, reaching peak expression of >100-fold over that in mock-infected animals. Moreover, mice receiving a VRP footpad inoculation 6, 12, or 24 h prior to an otherwise lethal VEE footpad challenge were completely protected from death, including a drastic reduction in challenge virus titers. VRP pretreatment also provided protection from intranasal VEE challenge and extended the average survival time following intracranial challenge. Signaling through the interferon receptor was necessary for antiviral gene induction and protection from VEE challenge. However, VRP pretreatment failed to protect mice from a heterologous, lethal challenge with vesicular stomatitis virus, yet conferred protection following challenge with influenza virus. Collectively, these results document a rapid modulation of the host innate response within hours of infection, capable of rapidly alerting the entire animal to pathogen invasion and leading to protection from viral disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19793821      PMCID: PMC2786707          DOI: 10.1128/JVI.00564-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

Review 1.  Alphavirus vectors for vaccine production and gene therapy.

Authors:  Kenneth Lundstrom
Journal:  Expert Rev Vaccines       Date:  2003-06       Impact factor: 5.217

Review 2.  Viruses and interferon: a fight for supremacy.

Authors:  Michael G Katze; Yupeng He; Michael Gale
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

Review 3.  Type I interferons in host defense.

Authors:  Daniel B Stetson; Ruslan Medzhitov
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

4.  A single-site mutant and revertants arising in vivo define early steps in the pathogenesis of Venezuelan equine encephalitis virus.

Authors:  J F Aronson; F B Grieder; N L Davis; P C Charles; T Knott; K Brown; R E Johnston
Journal:  Virology       Date:  2000-04-25       Impact factor: 3.616

5.  Exhaustion of type I interferon response following an acute viral infection.

Authors:  Mohammed Alsharifi; Matthias Regner; Robert Blanden; Mario Lobigs; Eva Lee; Aulikki Koskinen; Arno Müllbacher
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

6.  Mouse p56 blocks a distinct function of eukaryotic initiation factor 3 in translation initiation.

Authors:  Daniel J Hui; Fulvia Terenzi; William C Merrick; Ganes C Sen
Journal:  J Biol Chem       Date:  2004-11-23       Impact factor: 5.157

7.  Immunopathogenesis and immune modulation of Venezuelan equine encephalitis virus-induced disease in the mouse.

Authors:  P C Charles; J Trgovcich; N L Davis; R E Johnston
Journal:  Virology       Date:  2001-06-05       Impact factor: 3.616

8.  Epidemic Venezuelan equine encephalitis in La Guajira, Colombia, 1995.

Authors:  F Rivas; L A Diaz; V M Cardenas; E Daza; L Bruzon; A Alcala; O De la Hoz; F M Caceres; G Aristizabal; J W Martinez; D Revelo; F De la Hoz; J Boshell; T Camacho; L Calderon; V A Olano; L I Villarreal; D Roselli; G Alvarez; G Ludwig; T Tsai
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

9.  Coordinated regulation and widespread cellular expression of interferon-stimulated genes (ISG) ISG-49, ISG-54, and ISG-56 in the central nervous system after infection with distinct viruses.

Authors:  Christie Wacher; Marcus Müller; Markus J Hofer; Daniel R Getts; Regina Zabaras; Shalina S Ousman; Fulvia Terenzi; Ganes C Sen; Nicholas J C King; Iain L Campbell
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Interferon induction and sensitivity as correlates to virulence of Venezuelan encephalitis viruses for hamsters.

Authors:  P B Jahrling; E Navarro; W F Scherer
Journal:  Arch Virol       Date:  1976       Impact factor: 2.574

View more
  13 in total

1.  Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge.

Authors:  Christopher H Logue; Aaron T Phillips; Eric C Mossel; Jeremy P Ledermann; Thomas Welte; Steve W Dow; Ken E Olson; Ann M Powers
Journal:  Antiviral Res       Date:  2010-05-07       Impact factor: 5.970

2.  Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge.

Authors:  Kimberly A Dodd; Brian H Bird; Maureen G Metcalfe; Stuart T Nichol; César G Albariño
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

3.  The role of the blood-brain barrier during Venezuelan equine encephalitis virus infection.

Authors:  Alexandra Schäfer; Christopher B Brooke; Alan C Whitmore; Robert E Johnston
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

4.  Hypervariable Domain of nsP3 of Eastern Equine Encephalitis Virus Is a Critical Determinant of Viral Virulence.

Authors:  Chetan D Meshram; Nikita Shiliaev; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

5.  Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation.

Authors:  Svetlana Atasheva; Dal Young Kim; Maryna Akhrymuk; David G Morgan; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

6.  Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates.

Authors:  John T Bates; Jennifer A Pickens; Jennifer E Schuster; Monika Johnson; Sharon J Tollefson; John V Williams; Nancy L Davis; Robert E Johnston; Nancy Schultz-Darken; James C Slaughter; Frances Smith-House; James E Crowe
Journal:  Vaccine       Date:  2016-01-07       Impact factor: 3.641

7.  Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs.

Authors:  Dal Young Kim; Svetlana Atasheva; Alexander J McAuley; Jessica A Plante; Elena I Frolova; David W C Beasley; Ilya Frolov
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-07       Impact factor: 11.205

8.  Venezuelan equine encephalitis replicon particles can induce rapid protection against foot-and-mouth disease virus.

Authors:  Fayna Diaz-San Segundo; Camila C A Dias; Mauro P Moraes; Marcelo Weiss; Eva Perez-Martin; Gary Owens; Max Custer; Kurt Kamrud; Teresa de los Santos; Marvin J Grubman
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

9.  Antiviral Effects of Novel Herbal Medicine KIOM-C, on Diverse Viruses.

Authors:  Melbourne R Talactac; Mohammed Y E Chowdhury; Min-Eun Park; Prasanna Weeratunga; Tae-Hwan Kim; Won-Kyung Cho; Chul-Joong Kim; Jin Yeul Ma; Jong-Soo Lee
Journal:  PLoS One       Date:  2015-05-05       Impact factor: 3.240

10.  Epimedium koreanum Nakai displays broad spectrum of antiviral activity in vitro and in vivo by inducing cellular antiviral state.

Authors:  Won-Kyung Cho; Prasanna Weeratunga; Byeong-Hoon Lee; Jun-Seol Park; Chul-Joong Kim; Jin Yeul Ma; Jong-Soo Lee
Journal:  Viruses       Date:  2015-01-20       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.